Pharmaceuticals
Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar
SHANGHAI, July 30, 2020 /PRNewswire/ -- The European Commission (EC) has approved Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthcare Limited (Accord)'s Zercepac®, a biosimilar trastuzumab, for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive meta...
2020-07-30 08:00
5665
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pennsylvania, July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomat...
2020-07-29 19:30
4794
Atomo Diagnostics and Access Bio partner to expand access to COVID-19 blood-based rapid testing in North America
SYDNEY, July 29, 2020 /PRNewswire/ -- Atomo has announced that it has signed a binding agreement with US-based diagnostics specialist Access Bio Inc. (KOSDAQ: 950130) (Access Bio) that will see Atomo supply its unique, integrated rapid diagnostic test (RDT) devices to Access Bio for use with its ...
2020-07-29 08:47
2761
Oscotec to Use CDD Vault to Manage Its Chemistry and Biological Research Data
The company selected the platform to help streamline its drug discovery data management process SEONGNAM-SI, South Korea and BURLINGAME, California, July 29, 2020 /PRNewswire/ -- Oscotec, a Korean biotech company engaged in the clinical stage discovery of novel drug candidates for unmet needs, a...
2020-07-29 07:00
5222
Jubilant Biosys Limited announces the merger with Jubilant Chemsys Limited
BENGALURU, India, July 28, 2020 /PRNewswire/ -- Jubilant Biosys Limited ("Biosys"), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida,India. The combined entities will now operate ...
2020-07-28 20:27
5124
"White Mouse in Water" - Infinitus Develops New Technology of Using Zebrafish for Health Products Screening
GUANGZHOU, China, July 28, 2020 /PRNewswire/ -- Recently, the Chinese Institute of Food Science and Technology (CIFST) brought together experts inBeijing to evaluate the results of a collaborative R&D effort between Infinitus (China) Company Ltd. and Hangzhou Hunter Biotechnology Co., Ltd., named...
2020-07-28 20:00
4757
New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals' Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asia
IRVINE, Calif. and HONG KONG, July 28, 2020 /PRNewswire/ -- IACTA Pharmaceuticals, Inc. ("IACTA" or the "Company") and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited ("ZKO"), a leadingHong Kong-based pharmaceutical company, today announces they have entered into a definitive license agr...
2020-07-28 17:59
3851
AGC to Complete the Acquisition of MolMed on July 31, 2020
AGC Biologics adds leading-edge cell & gene therapy company in Milan, Italy SEATTLE, July 28, 2020 /PRNewswire/ -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire the majority of the share capital of Molec...
2020-07-28 10:00
3804
Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA
HANGZHOU, China, July 27, 2020 /PRNewswire/ -- Lynk Pharmaceuticals (Hangzhou, China) is pleased to announce exclusive licensing agreements with Kobe University (Kobe, Japan) and with RIKEN Research Institute (Saitama, Japan) to develop RAS inhibitors with a novel MOA. The agreement withKobe Univ...
2020-07-27 07:00
4142
N.B. Quadriga's Transformative Treatment for Brain Cancers Dosed in First Human Subject
SHANGHAI and NANTONG, China, July 23, 2020 /PRNewswire/ -- N.B. Quadriga (NBQ), a clinical stage biopharmaceutical company developing transformative medicines for brain cancers, today announced that the first patient has been dosed in a Phase 1 study of NBQ72S, also known as QBS10072S, in pati...
2020-07-23 19:00
3978
Zhongchao Inc. Joined Hands with Professional Non-Profit Organizations and 9 Leading Pharma Companies to Carry Out Multi-Year Online Education Project on Diagnosis and Treatment of Primary Liver Cancer
SHANGHAI, July 23, 2020 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it joined hands with China Health P...
2020-07-23 18:30
4410
Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China
SUZHOU, China and ROCKVILLE, Md., July 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of t...
2020-07-22 17:31
2335
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
SHANGHAI and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib...
2020-07-20 22:39
4998
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses With Eureka Therapeutics' Solid Tumor Technologies in China
SHANGHAI and EMERYVILLE, Calif., July 20, 2020 /PRNewswire/ -- JW Therapeutics
2020-07-20 21:33
4715
Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
SAN DIEGO and TAICANG, SUZHOU, China, July 20, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced that the first patient has been dosed in a Phase 2 clinical tria...
2020-07-20 20:00
2797
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
SHANGHAI, July 20, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, today announced that it has successfully closed...
2020-07-20 08:00
9587
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 16, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced that the Company presented preclinical data from a fully human CD73 antibody (HBM1007) in an e-poster at the American...
2020-07-16 18:00
4286
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia
SUZHOU, China and ROCKVILLE, Md., July 15, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug A...
2020-07-15 21:07
2328
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia
SAN DIEGO and SAFFRON WALDEN, United Kingdom, July 14, 2020 /PRNewswire/ -- Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise ...
2020-07-14 18:00
2873
Zuellig Pharma appoints John Graham as new CEO
SINGAPORE, July 14, 2020 /PRNewswire/ -- Zuellig Pharma, a leading healthcare
services provider inAsia, announces the appointment of John Graham as its new
CEO. John will run theUS$13 billion business and lead the team across 13
markets inAsia.
2020-07-14 09:00
9581
Week's Top Stories
Most Reposted
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 293 media titles]
2025-01-23 09:00
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 291 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
7665
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5438